FDA issued 303 Warning Letters to drug and biologics manufacturers in fiscal year 2025 — up 59% from 190 in FY2024. A senior FDA official put the Center for Drug Evaluation and Research's own increase at roughly 50% over the same period (RAPS, Dec 2025). Neither number is a rounding error, and neither looks like a one-year spike: CDER added roughly 30 more Warning Letters by early March 2026 and another 25 by mid-June, according to ongoing trade-press tracking of FDA's public Warning Letters database.
If your compliance team has felt like FDA correspondence is landing more often this year, the data backs that up. Here's what's driving it, and what it changes about how a compliance team should operate.
What's driving the increase
Trade coverage of FY2025's Warning Letter data points to a few concentrated areas: unapproved and misbranded drug products (including a wave of letters to telehealth platforms selling compounded GLP-1 products), and CGMP data-integrity findings at both domestic and foreign facilities. Laboratory-record citations under 21 CFR 211.194(a) — incomplete or fabricated test data — show up repeatedly across recent letters, including the widely covered Warning Letter to Huons Co., Ltd. on June 15, 2026, which cited five distinct subsections of 21 CFR 211.
Leadership at FDA has changed hands during this period — Commissioner Marty Makary resigned in May 2026, with Kyle Diamantas serving as acting commissioner (NPR) — and enforcement volume didn't dip through the transition. That continuity is itself informative: the surge looks like agency posture, not one person's initiative, which means it's a reasonable planning assumption for the rest of 2026 rather than a trend that reverses with the next appointee.
The staffing math makes it harder to keep up manually
The letter volume is rising at the same time FDA's own workforce has shrunk. Reporting on the DOGE-driven HHS restructuring puts FDA's 2025 staff reductions at roughly 3,859 employees, with separated inspectors averaging 19 years of experience (FedScoop; Morgan Lewis). On the receiving end, pharma and biotech companies cut more than 14,180 jobs across 25-plus companies in the first half of 2026 alone, and quality/compliance roles haven't been exempt — Novo Nordisk's broader reduction included cuts to quality-control staff (PharmaVoice).
Put together: more enforcement documents, a leaner regulator producing them, and leaner teams reading them. That's the case for why "someone checks fda.gov when they have time" stops being an adequate process at this volume.
What this means for your compliance team
A few practical implications follow directly from the numbers:
- Assume the current pace continues. Enforcement volume held steady through a commissioner transition, so build 2026 planning around sustained ~50%+ higher letter volume rather than treating FY2025 as a peak year.
- Data integrity is the highest-frequency citation category. If your CDMOs or your own facilities have any gap in lab-record completeness or chain-of-custody documentation, that's the first place FDA is looking.
- Foreign-facility oversight deserves a second look. Several of the highest-profile 2026 letters, including Huons Co. and Wizcure Pharmaa, involved foreign CDMOs — worth a specific line item in your supply-chain risk review if you depend on offshore manufacturing.
- Don't assume FDA's own reduced headcount means less scrutiny. The data says the opposite: a smaller agency is producing more, not fewer, Warning Letters, likely by concentrating remaining capacity on the highest-signal enforcement action available.
- Build monitoring into the daily workflow, not the weekly one. At FY2025-2026 volume, a once-a-week fda.gov scrape means letters relevant to your watchlist sit unread for days. A same-day-to-next-morning process closes that gap without adding headcount.
Argus reads every FDA Warning Letter the day it publishes and delivers the ones matching your watchlist — CDMOs, competitors, therapeutic areas — by 6am ET the next business day, with severity, CFR citations, and a verbatim fda.gov link on every item. Built for a compliance team doing more enforcement-tracking with the same headcount, not more.
Sources: RAPS, NPR, FedScoop, Morgan Lewis, PharmaVoice. See the full Why Now analysis for additional sourcing.